HealthEquity Inc. (HQY)
Why HealthEquity Stock Sank This Week
HealthEquity posted significant sales and earnings beats with its fiscal Q2 report. The company issued a small increase for its full-year guidance, but management kept its forecast for adjusted earnings per share the same.
HealthEquity, Inc. (HQY) Q2 2027 Earnings Call Transcript
HealthEquity, Inc. (HQY) Q2 2027 Earnings Call Transcript
HealthEquity Q2 Earnings Call Highlights
HealthEquity NASDAQ: HQY reported accelerated revenue growth and record profitability in its fiscal 2027 second quarter, citing HSA account expansion, higher member engagement and technology-driven service efficiencies. The company raised its full-year outlook after generating record adjusted EBITDA margin of 48%.
HealthEquity (HQY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended July 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
HealthEquity (HQY) Q2 Earnings and Revenues Top Estimates
HealthEquity (HQY) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $1.08 per share a year ago.
Ahead of HealthEquity (HQY) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for HealthEquity (HQY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2026.
HealthEquity (HQY) Upgraded to Buy: What Does It Mean for the Stock?
HealthEquity (HQY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HealthEquity's Earnings Momentum Deserves More Credit
HealthEquity is the leading HSA and CDB administrator, consistently beating revenue and EPS expectations with strong operational execution. HQY's fiscal 2027 revenue is guided to $1.41–$1.42 billion, with robust HSA asset growth, margin expansion, and accelerating buybacks supporting a Buy rating. Custodial yield remains resilient at 3.84%, supported by rate locks through 2029, while automation and AI investments drive significant cost efficiencies.
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY benefits from strong HSA growth, AI-driven automation and solid first-quarter fiscal 2027 results despite data security risks.
Here's Why HealthEquity (HQY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why HealthEquity (HQY) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
